ERBB2 and gastric cancer: During the last decade several nonchemotherapy treatments for gastric cancer have emerged, such as trastuzumab which has shown improved overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2) positive disease when added to standard chemotherapy.7